Horizon Discovery Group plc, today announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon’s proprietary technologies.
Horizon Discovery, today announces the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard to support the validation of Next Generation Sequencing (NGS) assays.
Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation.
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated.
Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand clinical investigation and what is its future potential?
From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.
Imaging has long been indispensable in clinical practice, and researchers have for many years used the same toolbox of imaging modalities as a component of their preclinical and drug development work.
Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel tumour dependencies and molecular targets.